A Laparoscopic Rental Denervation (RDN) Device HyperQure Begins U.S. Clinical Trials

DeepQure, a well-known name in medical technology, is advancing its laparoscopic Rental Denervation (RDN) device, HyperQure, into U.S. clinical trials. This device aims to treat resistant hypertension, a condition where blood pressure remains high despite medication.

Clinical Trials Approval

HyperQure has received IRB (Institutional Review Board) approval from top U.S. institutions. The approved sites include:

• University of California, Irvine
• Mayo Clinic

Additionally, other prominent hospitals are in the process of gaining the same approval, such as:

• Stanford University
• Emory University Medical Center
• University of Arizona
• University of Florida
• Henry Ford Health System

What’s Next for HyperQure?

DeepQure has completed the initial screening and plans to perform the first laparoscopic RDN surgery in the U.S. in January. The goal is to enroll 15 patients for clinical testing by mid-2025. The trials will focus on demonstrating the safety and effectiveness of HyperQure for treating resistant hypertension.

FDA and IRB Milestones

DeepQure achieved significant progress by obtaining FDA’s Investigational Device Exemption (IDE) and IRB approvals quickly within three months from leading U.S. institutions. The company aims to grow the clinical use of HyperQure through these trials.

Innovative Approach to Hypertension

HyperQure represents a breakthrough as the first laparoscopic RDN device for resistant hypertension. It belongs to the Class III medical device category, requiring pre-market approval through extensive clinical testing.

Benefits of HyperQure

• Specifically designed for resistant hypertension
• Laparoscopic approach leads to minimally invasive procedures
• Potentially higher success rates and fewer complications

Key Considerations

If you’re affected by resistant hypertension, it’s essential to track developments with HyperQure. Here’s why:

• Improved treatment outcomes if successful
• Potentially fewer side effects with laparoscopic technique
• Availability might signal shifts in treatment protocols for hypertension

DeepQure’s Commitment

DeepQure aims to start clinical procedures in January, focusing on patient safety and device efficacy. This trial is pivotal in solidifying HyperQure’s place in medical history.

Tags for Updates

To stay informed, follow:

• DeepQure
• Laparoscopic RDN
• HyperQure
• Resistant hypertension treatment
• FDA approval processes

HyperQure is a part of a series of transformative initiatives in the healthcare industry that aim to improve patient outcomes with innovative medical technologies. Keep an eye on this page for the latest updates on HyperQure’s journey through U.S. clinical trials.

Table of Contents:

1. Introduction
   • 1.1 Overview of HyperQure and Its Significance
   • 1.2 Importance of Addressing Resistant Hypertension
2. Clinical Trials Approval
   • 2.1 Sites Approved for Clinical Trials
     • 2.1.1 University of California, Irvine
     • 2.1.2 Mayo Clinic
     • 2.1.3 Other Prominent Institutions
   • 2.2 Current Approval Status
3. What’s Next for HyperQure?
   • 3.1 Initial Screening and Surgical Plans
   • 3.2 Patient Enrollment Goals
4. FDA and IRB Milestones
   • 4.1 Overview of Approval Processes
   • 4.2 Importance of IDE and IRB Approvals
5. Innovative Approach to Hypertension
   • 5.1 Breakthrough in Laparoscopic RDN Technology
   • 5.2 Class III Medical Device Classification
6. Benefits of HyperQure
   • 6.1 Designed for Resistant Hypertension
   • 6.2 Minimally Invasive Procedure Advantages
   • 6.3 Higher Success Rates and Lower Complications
7. Key Considerations for Patients
   • 7.1 Tracking Developments with HyperQure
   • 7.2 Potential Treatment Outcomes
   • 7.3 Impacts on Treatment Protocols
8. DeepQure’s Commitment
   • 8.1 Focus on Patient Safety and Device Efficacy
   • 8.2 Importance of Clinical Trials in Medical Advancement
9. Tags for Updates
   • 9.1 Follow for Latest News on HyperQure
10. Conclusion

• 10.1 Summary of HyperQure’s Clinical Trial Journey
• 10.2 Future Implications for Treatment of Resistant Hypertension